Drug Target Discovery in Mast Cells by GECKO Technology

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$99,800.00
Award Year:
2003
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI056636-01
Award Id:
65911
Agency Tracking Number:
AI056636
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
ATHERSYS, INC., 3201 CARNEGIE AVE, CLEVELAND, OH, 44115
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
PAUL JACKSON
(216) 431-9900
PDJACKSON@ATHERSYS.COM
Business Contact:
(216) 431-9900
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): The goal of the present research program is to utilize a genome-wide, high-throughput gene knock-out technology in combination with cellular assays to identify anti-inflammatory drug targets. This novel knockout technology, termed Genome-wide Cell-based Knockout technology or GECKO, is capable of inactivating expression of each transcriptionally active gene in cultured cells. Genome-wide GECKO libraries contain a relatively small number of clones, typically less than 1,000,000 clones, wherein each clone contains a different gene knockout, and collectively each transcriptionally active gene has been knocked out within the library. In this phase I research program, we will establish mast cell activation assays compatible with the GECKO technology, and create a genome-wide GECKO library for identification of genes whose function is necessary for mast cell degranulation. The specific aims of this phase I program, therefore, are 1) to develop robust high-throughput assays to enable screens for mast cell mutants with defective activation and degranulation responses.; and 2) to generate a phenotypically stable, genome-wide, GECKO library for use in identifying degranulation mutants in the chosen mast cell model. Success in this Phase I program will enable a full scale effort to identify genes that inhibit various mast cell functions involved in allergy, asthma, and anaphylaxis as well as in degenerative fibrosis and arthritis, and thereby identify new drug targets for the treatment of inflammatory diseases.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government